

ISSUE @ A GLANCE



Cardio-oncology: a focus on cardiovascular toxicities of cancer therapies and on atrial fibrillation in cancer

F. Crea

245

CardioPulse

How to live to 100 before developing clinical coronary artery disease: a suggestion

E. Braunwald

249

Screening professional athletes for cardiovascular diseases at risk of cardiac arrest

D. Corrado, A. Pelliccia, C. Basso, and A. Zorzi

251

Leading the cardiology arena in Egypt

M. Nicholls

255

Use of chronic kidney disease blind spot to prevent cardiorenal outcomes

L.M. Ruilope, G. Ruiz-Hurtado, B. Miranda, and A. Ortiz

257

Weekly Journal Scan

Implantable recorders and systematic atrial fibrillation detection do not outperform standard of care in stroke prevention in the LOOP study

M.L. Narducci and M. Volpe

261

SPECIAL ARTICLE

Diabetes and Metabolic Disorders

The year in cardiovascular medicine 2021: diabetes and metabolic disorders

F. Cosentino, D.L. Bhatt, N. Marx, and S. Verma

263

Digital Health and Innovation

The year in cardiovascular medicine 2021: digital health and innovation

P.E. Vardas, F.W. Asselbergs, M. van Smeden, and P. Friedman

271

Cardio-Oncology

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement*

J. Herrmann, D. Lenihan, S. Armenian, A. Barac, A. Blaes, D. Cardinale, J. Carver, S. Dent, B. Ky, A.R. Lyon, T. López-Fernández, M.G. Fradley, S. Ganatra, G. Curigliano, J.D. Mitchell, G. Minotti, N.N. Lang, J.E. Liu, T.G. Neilan, A. Nohria, R. O'Quinn, I. Pusic, C. Porter, K.L. Reynolds, K.J. Ruddy, P. Thavendiranathan, and P. Valent

280

FAST TRACK CLINICAL RESEARCH

Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis

A. Guha, M.G. Fradley, S.F. Dent, N.L. Weintraub, M.B. Lustberg, A. Alonso, and D. Addison

300

Editorial

Atrial fibrillation and breast cancer: casual or causal relationship?

J.L. Merino

313

CLINICAL RESEARCH

Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy

L. Michel, I. Helfrich, U.B. Hendgen-Cotta, R.-I. Mincu, S. Korste, S.M. Mroczek, A. Spomer, A. Odersky, C. Rischpler, K. Herrmann, L. Umutlu, C. Coman, R. Ahrends, A. Sickmann, S. Löffek, E. Livingstone, S. Ugurel, L. Zimmer, M. Gunzer, D. Schadendorf, M. Totzek, and T. Rassaf

316

Editorial

Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments

G. Varricchi, M.R. Galdiero, and C.G. Tocchetti

330

Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis

O.C. Cohen, A. Ismael, B. Pawarova, R. Manwani, S. Ravichandran, S. Law, D. Foard, A. Petrie, S. Ward, B. Douglas, A. Martinez-Naharro, L. Chacko, C.C. Quarta, S. Mahmood, S. Sachchithanatham, H.J. Lachmann, P.N. Hawkins, J.D. Gillmore, M. Fontana, R.H. Falk, C.J. Whelan, and A.D. Wechalekar

333

Editorial

 Longitudinal strain in the management of cardiac AL amyloidosis: do we need it?

C. Rapezzi, A. Aimo, and R. Pavesini

342

DISCUSSION FORUM

Iron therapy on quality of life in acute heart failure: alternative approaches

K.T. Sawicki and H. Ardehali

345

Dilemmas on diagnosis and treatment of iron deficiency in patients after an episode of acute heart failure

E.A. Jankowska and P. Ponikowski

347

CARDIOVASCULAR FLASHLIGHT

How to escape a catastrophic myocardial rupture by a whisker

M. Barker, M.B. Iqbal, K. Shetty, and M.B. Sikkal

349

Primary malignant fibrous histiocytoma of the mitral valve as a rare incidental finding

A. Idris, R.L. Smith II, W.H. Ryan, and Z. Wang

350

*This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>

 Open Access Paper

 For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



www.eurheartj.org